On Tuesday, Blackstone Group LP (NYSE:BX)’s shares inclined 1.40% to $38.63.
Blackstone Mortgage Trust, Inc. (BXMT) stated its second quarter 2015 results. Net income for the second quarter was $29 million, or $0.36 per share.
The Blackstone Group L.P. is a publicly owned investment manager. The firm also provides financial advisory services to its clients. It provides its services to public and corporate pension funds, academic, cultural, and charitable organizations. The firm manages separate client focused portfolios. It launches and manages private equity funds, real estate funds, funds of hedge funds, and credit-focused funds for its clients.
LendingClub Corp (NYSE:LC)’s shares gained 3.21% to $14.81.
Lending Club (LC), the world’s largest online marketplace connecting borrowers and investors, recently declared it plans to issue its earnings release for the second quarter ended June 30, 2015, on Tuesday, August 4, 2015, after the market close. Lending Club will host a conference call to talk about the second quarter 2015 financial results at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) on the same day.
LendingClub Corporation operates as an online marketplace for connecting borrowers and investors in the United States. Its marketplace facilitates various types of loan products for consumers and small businesses, counting unsecured personal loans, super prime consumer loans, unsecured education and patient finance loans, and unsecured small business loans.
At the end of Tuesday’s trade, Celgene Corporation (NASDAQ:CELG)‘s shares surged 2.16% to $135.42.
Celgene Corporation (CELG) declared that its direct wholly-owned partner, Strix Corporation, has commenced its formerly declared tender offer for all outstanding shares of common stock of Receptos, Inc. (RCPT) at a price of $232.00 per share, net to the seller in cash, without interest and less required withholding taxes. The tender offer is being made in connection with the Agreement and Plan of Merger, dated July 14, 2015, by and among Celgene, Strix Corporation and Receptos, Inc.
The board of directors of Receptos has unanimously determined that the offer is fair, advisable and in the best interests of Receptos and its stockholders and recommends that the stockholders of Receptos accept the offer and tender their shares.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers; POMALYST/IMNOVID for the treatment of multiple myeloma; and VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, in addition to acute myeloid leukemia (AML).
Arch Coal Inc (NYSE:ACI), ended its Tuesdays trading session with -8.30% loss, and closed at $0.190.
Arch Coal, Inc. (ACI) declared that for administrative purposes it is postponing its formerly declared one-for-ten reverse stock split of Arch’s common stock. The reverse stock split formerly was predictable to take place after market close on July 27, 2015. As a result of the postponement, the reverse stock split is predictable to take place after market close on August 3, 2015 (the “Effective Time”). It also is predictable that Arch’s common stock will start trading on a split-adjusted basis on the New York Stock Exchange (“NYSE”) at the market open on August 4, 2015.
Arch Coal, Inc. produces and sells thermal and metallurgical coal from surface and underground mines located in the United States. As of December 31, 2014, it operated or contracted out the operation of 16 mines; and owned or controlled about 5.1 billion tons of proven and probable recoverable reserves. A
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
